Summit Trail Advisors LLC Raises Position in GSK plc (NYSE:GSK)

Summit Trail Advisors LLC grew its position in shares of GSK plc (NYSE:GSK) by 19.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,834 shares of the pharmaceutical company’s stock after purchasing an additional 1,457 shares during the period. Summit Trail Advisors LLC’s holdings in GSK were worth $302,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Eastern Bank purchased a new stake in GSK during the 3rd quarter valued at $26,000. Sunbelt Securities Inc. increased its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Crews Bank & Trust purchased a new position in GSK in the 4th quarter worth about $26,000. Concord Wealth Partners lifted its stake in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares during the period. Finally, ST Germain D J Co. Inc. boosted its holdings in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday. They set an “equal weight” rating on the stock. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

NYSE GSK opened at $36.15 on Thursday. The stock has a market cap of $74.92 billion, a price-to-earnings ratio of 22.74, a PEG ratio of 1.42 and a beta of 0.64. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company’s 50 day moving average is $34.31 and its two-hundred day moving average is $37.51. The company has a current ratio of 0.78, a quick ratio of 0.53 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, research analysts anticipate that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.35%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 93.08%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.